Journey Medical (DERM) announced that full results from two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, Minocycline Versus Oracea in Rosacea-1 and Minocycline Versus Oracea in Rosacea-2, evaluating Minocycline Hydrochloride Extended Release Capsules, 40 mg for the treatment of moderate-to-severe papulopustular rosacea in adults were published in the Journal of the American Medical Association – Dermatology. The results demonstrated the efficacy, safety and tolerability of oral DFD-29 in rosacea.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
Questions or Comments about the article? Write to editor@tipranks.com